3721 Valley Centre Drive
At Retrophin, our corporate culture is defined by our mission, vision and values. Although you cannot see or touch our culture, it is very present in our actions and behaviors. At its core is our commitment to our mission – to identify, develop and deliver life-changing therapies to people living with rare diseases. This is what we do every day in our jobs by working hard, supporting our team members and living our values: Accountability, Entrepreneurial Spirit, Integrity, Patient Focus, Scientific Excellence and Teamwork. We strive to help our organization succeed by pursuing our vision – to become a preeminent, global and fully-integrated biopharmaceutical company within the rare disease community that is dedicated to giving patients a chance and providing hope. Our number one priority will always be the patients we serve – they are why we come to work every day, as patient-centricity permeates every aspect of our culture.
Our approach centers on our pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®. Our Total Care HUB® eases patients’ access to these products by offering personalized and comprehensive support services – at no cost to patients, physicians or insurance companies.
Please click here for Retrophin job opportunities.
Please click here for clinical trial information.
Stock Symbol: RTRX
Stock Exchange: NASDAQ
160 articles with Retrophin
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor conferences in March
Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
Retrophin, Inc. joins the National Organization for Rare Disorders, the European Organisation for Rare Diseases, and others worldwide to recognize Rare Disease Day® 2019.
Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York Cityon Thursday, February 28, 2019 at 3:30 p.m. ET.
Retrophin, Inc. announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets.
Top-line readout of pivotal FORT Study in PKAN expected 3Q19
Dr. Dube brings proven track record of global leadership built upon significant commercial and operational success
Retrophin, Inc. today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 at 11:00 a.m. PT (2:00 p.m. ET).
Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
Retrophin, Inc. announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy, a rare kidney disorder that often leads to end-stage renal disease
Top-line data anticipated in the third quarter of 2019
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Retrophin, Inc. today announced that Stephen Aselage, chief executive officer, will present at the BMO 2018 Prescriptions for Success Healthcare Conference in New York City on Wednesday, December 12, 2018 at 9:20 a.m. ET.
Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria
Retrophin, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new formulation of Thiola (tiopronin) in the treatment of cystinuria.
Retrophin, Inc. today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2018 London Healthcare Conference in London, UK on Wednesday, November 14, 2018 at 4:40 p.m. GMT (11:40 a.m. ET).
Pivotal programs enrolling towards first data readout in 2019
Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension
Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology
DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018
Retrophin, Inc. today announced it will report third quarter 2018 financial results on Thursday, November 1, 2018 after the close of the U.S. financial markets.
Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018
Retrophin, Inc. today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018.
Retrophin, Inc. today announced that presentations highlighting the design of the ongoing pivotal Phase 3 FORT Study of fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), the patient and caregiver experience with PKAN, and the diagnostic pathway and clinical experience of patients with PKAN, will be presented by the Company and its collaborators at upcoming medical congresses in October.